Home>>Natural Products>>Maohuoside A

Maohuoside A Sale

(Synonyms: 茂藿苷A) 目录号 : GC60239

MaohuosideA,一种从E.koreanum中分离出的单一化合物,可有效促进成骨作用。MaohuosideA通过骨形态发生蛋白(BMP)和MAPK信号通路增强了骨髓间充质干细胞的成骨作用。

Maohuoside A Chemical Structure

Cas No.:128988-55-6

规格 价格 库存 购买数量
1mg
¥1,800.00
现货
5mg
¥4,500.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Maohuoside A, a single compound isolated from the E. koreanum that potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways[1][2].

[1]. Ming Cai, et al. Maohuoside A Acts in a BMP-dependent Manner During Osteogenesis. Phytother Res. 2013 Aug;27(8):1179-84. [2]. Lei Yang, et al. Maohuoside A Promotes Osteogenesis of Rat Mesenchymal Stem Cells via BMP and MAPK Signaling Pathways. Mol Cell Biochem. 2011 Dec;358(1-2):37-44.

Chemical Properties

Cas No. 128988-55-6 SDF
别名 茂藿苷A
Canonical SMILES O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(CCC(C)(O)C)C(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)=CC(O)=C13
分子式 C27H32O12 分子量 548.54
溶解度 储存条件
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.823 mL 9.1151 mL 18.2302 mL
5 mM 0.3646 mL 1.823 mL 3.646 mL
10 mM 0.1823 mL 0.9115 mL 1.823 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Maohuoside A acts in a BMP-dependent manner during osteogenesis

Phytother Res 2013 Aug;27(8):1179-84.PMID:23007945DOI:10.1002/ptr.4840.

There has been a strong interest in searching for natural therapies for osteoporosis. Epimedium koreanum Nakai is an herb that is commonly used in East Asia to treat osteoporosis, and most studies of its activity have focused on its major ingredient, icariin. In this study, Maohuoside A (MHA), a single compound isolated from the E. koreanum, was found to promote osteogenesis in mouse bone marrow-derived mesenchymal stem cells. We hypothesise that, if MHA potently induces osteogenic differentiation in a bone morphogenetic protein-dependent manner, it may be used to broaden the sources for cell transplantation and thereby establish more efficient bone regeneration systems. Real-time polymerase chain reaction and western blot were used to detect the expression of SMAD4, a marker of bone formation. Microcomputed tomography and histomorphometric techniques showed that oral treatment with MHA was followed by an increase in the bone mineral density of the lumbar vertebrae in mice. This result also indicates that MHA may directly activate osteopontin gene transcription. In conclusion, MHA seems to enhance the osteogenesis of bone marrow-derived mesenchymal stem cells at least partly via bone morphogenetic protein signalling.

Maohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways

Mol Cell Biochem 2011 Dec;358(1-2):37-44.PMID:21698346DOI:10.1007/s11010-011-0918-y.

Osteoporosis is becoming a more prevalent health problem with the aging of the population around the world. Epimedium koreanum Nakai is one of the most used herbs in East Asia for curing osteoporosis, with its major ingredient, icariin, mostly explored by researchers. In this article, Maohuoside A (MHA), a single isolated compound from the herb, was identified to be more potent than icariin in promoting osteogenesis of rat bone marrow-derived mesenchymal stem cells (rMSCs) (increasing by 16.6, 33.3, and 15.8% on D3, D7, and D11, respectively). Alkaline phosphatase (ALP) assay and calcium content measurement were assigned to quantify the promoted osteogenesis and alizarin red S (ARS) staining was conducted to visualize it. Quantitative real-time PCR (Q-PCR) was assayed to evaluate the mRNA expression of marker genes in osteogenesis and master regulators in BMP pathway. Moreover, PD98059 (PD) and SB203580 (SB), inhibitor of ERK1/2 and p38 MAPK pathway, were administered to assess the involvement of MAPK pathway in the promotion process. In conclusion, MHA pronouncedly enhanced the osteogenesis of rMSC, plausibly via the BMP and MAPK signaling pathways.